KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.

Jay Parekh, Kaushal Parikh, Joshua E Reuss, Alex Friedlaender, Alfredo Addeo

Curr Oncol Rep 25(8) 913-922

PMID37249833
PMCIDPMC10326100
DOI10.1007/s11912-023-01430-4
发表日期2023-05-30
摘要

摘要

PURPOSE OF REVIEW: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates. RECENT FINDINGS: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with recent approvals in the peri-operative space, is now poised to transform the systemic treatment paradigm for localized and locally-advanced NSCLC. In this review, we focus on neoadjuvant ICB in resectable NSCLC, highlighting the pre-clinical rationale for neoadjuvant ICB, early clinical trials, randomized phase 3 trial data, and future directions for resectable NSCLC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。